<DOC>
	<DOC>NCT00607997</DOC>
	<brief_summary>This study will evaluate the overall remission rate of treatment with voreloxin Injection in patients at least 60 years of age with previously untreated AML</brief_summary>
	<brief_title>Study of Voreloxin in Older Patients With Untreated Acute Myeloid Leukemia</brief_title>
	<detailed_description>Other objectives of this study include: 1. Safety 2. Survival 3. Pharmacokinetics 4. Evaluate potential biomarkers</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<criteria>1. At least 60 years of age and diagnosis of previously untreated AML (either de novo or from an antecedent hematologic disorder or therapy related AML) 2. At least 20% blasts by BM biopsy or aspirate 3. ECOG performance status of 0,1,or 2 4. Adequate cardiac, renal and liver function 1. Uncontrolled DIC 2. Active central nervous system involvement by AML 3. Requiring hemodialysis or peritoneal dialysis 4. Some prior history of heart attack or stroke (depending on how long ago the event occurred)</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Myeloid</keyword>
	<keyword>Elderly</keyword>
	<keyword>Hematologic</keyword>
	<keyword>Blood</keyword>
	<keyword>Cancer</keyword>
	<keyword>Malignancy</keyword>
	<keyword>SNS-595</keyword>
	<keyword>Sunesis</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Older</keyword>
	<keyword>voreloxin</keyword>
	<keyword>reveal-1</keyword>
</DOC>